![Hamish Alan Cameron](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Hamish Alan Cameron
Private Equity Investor chez
SV Health Investors LLP
Profil
Hamish Alan Cameron currently works at SV Health Investors LLP, as Venture Partner and The Royal College of Physicians, as Member.
Dr. Cameron also formerly worked at MedImmune Ltd., as Chief Executive Officer from 2006 to 2008, X2-Pharma GmbH, as Chief Executive Officer, Cell Medica Switzerland AG, as Chief Executive Officer & Director, TopiVert Ltd., as Chairman & Interim Chief Executive Officer, Artios Pharma Ltd., as Director, Affinium Pharmaceuticals Ltd., as Director, Faculty of Pharmaceutical Medicine, as Director, VHsquared Ltd., as Director, AstraZeneca PLC, as Senior Vice President-Medical Research, Janssen-Cilag Ltd., as Principal, and ESBATech, a Novartis Co. GmbH, as Chief Commercial Officer.
Dr. Cameron received his undergraduate degree and doctorate degree from the University of London.
Postes actifs de Hamish Alan Cameron
| Sociétés | Poste | Début |
|---|---|---|
SV Health Investors LLP
 SV Health Investors LLP Investment ManagersFinance SV Health Investors invests in companies located across the Globe. The firm focuses on biotechnology, pharmaceuticals, medical devices & instruments and healthcare services sectors. It provides financing for seed, early, growth stage and buyout capital requirements. | Private Equity Investor | 02/01/2008 |
The Royal College of Physicians
 The Royal College of Physicians Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Anciens postes connus de Hamish Alan Cameron
| Sociétés | Poste | Fin |
|---|---|---|
TopiVert Ltd.
 TopiVert Ltd. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company developing medicines for the treatment of chronic inflammatory diseases of gastrointestinal (GI) tract and the eye | Directeur Général | 31/12/2020 |
MedImmune Ltd.
 MedImmune Ltd. BiotechnologyHealth Technology Engages in research and development of human monoclonal antibodies | Directeur Général | 01/01/2008 |
Artios Pharma Ltd.
 Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products for cancer treatment | Directeur/Membre du Conseil | - |
Janssen-Cilag Ltd.
 Janssen-Cilag Ltd. Pharmaceuticals: MajorHealth Technology Provides pharmaceutical products and services | Corporate Officer/Principal | - |
| ASTRAZENECA PLC | Corporate Officer/Principal | - |
Formation de Hamish Alan Cameron
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
96
Relations au 1er degré
14
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 14 |
|---|---|
AstraZeneca PLC
 AstraZeneca PLC Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
MedImmune Ltd.
MedImmune Ltd. BiotechnologyHealth Technology Engages in research and development of human monoclonal antibodies | Health Technology |
SV Health Investors LLP
SV Health Investors LLP Investment ManagersFinance SV Health Investors invests in companies located across the Globe. The firm focuses on biotechnology, pharmaceuticals, medical devices & instruments and healthcare services sectors. It provides financing for seed, early, growth stage and buyout capital requirements. | Finance |
Janssen-Cilag Ltd.
Janssen-Cilag Ltd. Pharmaceuticals: MajorHealth Technology Provides pharmaceutical products and services | Health Technology |
University of London
 University of London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
ESBATech, a Novartis Co. GmbH
 ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services Develops antibody fragment therapeutics | Commercial Services |
Affinium Pharmaceuticals Ltd.
 Affinium Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Provides clinical development of antibacterial | Health Technology |
The Royal College of Physicians
The Royal College of Physicians Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Faculty of Pharmaceutical Medicine | |
X2-Pharma GmbH
 X2-Pharma GmbH Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products for the treatment of inflammatory diseases. | Health Technology |
Cell Medica Switzerland AG
 Cell Medica Switzerland AG Pharmaceuticals: MajorHealth Technology Researches, develops, manufactures, and distributes pharmaceutical, biological, medical, and diagnostic products | Health Technology |
TopiVert Ltd.
TopiVert Ltd. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company developing medicines for the treatment of chronic inflammatory diseases of gastrointestinal (GI) tract and the eye | Health Technology |
VHsquared Ltd.
 VHsquared Ltd. BiotechnologyHealth Technology Develops antibody domain products against gastro intestinal infectious and immune mediated diseases | Health Technology |
Artios Pharma Ltd.
Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products for cancer treatment | Health Technology |
